Treatment of MDS patients with recombinant human erythropoietin and the role of GSTs

Journal of Experimental and Clinical Cancer Research

Volumn 23, Issue 3, 2004, Pages 417-424

  Tsabouri, S E ^a   Georgiou, I ^a   Katsaraki, A ^a   Bourantas, K L ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Erythropoietin treatment; Glutathione s transferase; Myelodysplastic syndromes

Indexed keywords

CARCINOGEN; ERYTHROPOIETIN; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; HEMOGLOBIN; ISOENZYME; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLAST CELL; BLOOD TRANSFUSION; BONE MARROW CELL; CLINICAL ARTICLE; DETOXIFICATION; DNA DETERMINATION; DOSE RESPONSE; DRUG EFFICACY; ENZYME POLYMORPHISM; ERYTHROID CELL; FEMALE; GENE DELETION; GENOTYPE; HEMOGLOBIN DETERMINATION; HOMOZYGOSITY; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE; MALE; MYELODYSPLASTIC SYNDROME; NULL ALLELE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALLELES; BLOOD PLATELETS; BLOOD TRANSFUSION; BONE MARROW CELLS; DNA; ERYTHROCYTES; ERYTHROPOIETIN; FEMALE; GENE DELETION; GENOTYPE; GLUTATHIONE TRANSFERASE; HEMOGLOBINS; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 8644232536     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Koeffler M.P.: Myelodysplastic syndromes (preleukemia). Semin. Hematol. 23(4):284-299, 1986.
2. Jacobs A., Clark R.E.: Pathogenesis and Clinical variations in the myelodysplastic syndromes. Clinics in Haematol. 15:925-951, 1986.
3. Dormer P., Hershko C., Wilmanns W.: Mechanisms and prognostic value of cell kinetics in the myelodysplastic syndromes. Br. J. Haematol. 67:147-152, 1987.
4. Janssen J.W.G., Buschle M., Layton I., et al: Clonal analysis of myeolodysplastic syndromes: Evidence of mutlipotent stem cell origin. Blood 73(1):248-254, 1989.
5. Benett J.M., Catovsky D., Daniel M.I., Flandrin G., Galton D.A.G., Granlick M.R., Sultan C.: The French-American-British (FAB) Co-operative Group: Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51(2):189-190, 1982.
6. Coiffie B., Adeleine P., Viala I.J., Byron P.A., Fiere D., Gentilhomme O., Vuran H.: Dysmyelopoieitc syndromes. A search of prognostic factors 193 patients. Cancer 1;52(1):83-90, 1983.
7. Mufti G.J., Stevens J.R., Oscier D.O., Hamblin T.J., Machin J.: Myelodysplastic syndromes. A system with prognostic significance. Br. J. Haematol. 59(3):425-433, 1985.
8. Cheson B.D.: The myelodysplastic syndromes: Current Approaches to Therapy. Annals of Internal Medicine 112(12):932-939, 1990.
9. Ketterer B.: Protective role of glutathione transferases in mutagenesis and carcinogenesis. Mutat. Res. 202(2):343-361, 1998.
10. Hayes J.D., and Pulford D.J.: The glutathiuone S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30:445-600, 1999.
11. Peters W.H.M., Kock L., Nagengast F.M., and Kremers P.O.: Biotransformation enzymes in human intestine: critical low levels in the colon? Gut 32:408-412, 1991.
12. Mannervik B., and Danielsson U.H.: Glutathione S-transferases. Structure and catalytic activity. CRC Crit. Rev. Biochem. 23:283-337, 1988.
13. Black S.M., and Wolf C.R.: The role of glutathione-dependent enzymes in drug resistance. Pharmac. Ther. 51:139-154, 1991.
14. Tsuchida S. and Sato K.: Glutathione transferases and cancer. Crit. Rev. Biochem. Mol. Biol. 27:337-384, 1992.
15. Moscow J.A., and Dixon K.M.: Glutathione-related enzymes, glutathione and multidrug resistance. Cytotechnology 12:155-170, 1993.
16. Tew K.D.: Glutathione-associated enzymes in anti-cancer drug resistance. Cancer Res. 54:4313-4320, 1994.
17. Board P.O., Caggan M., Johnston P., Ress V, Suzuki T et al.: Genetic heterogeneity of the human glutathione transferases: a complex of gene families: Pharmacol. Ther. 48:357-369, 1990.
18. Anderson I.E., Appelbaum F.R., Fisher L.D., Schoch G., Shulman H., Anasetti C., Bensinger W.J., Bryant E., Buckner C.D., Dorey K. et al.: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 15;82(2):677-681, 1993.
19. Casadevall N.: Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes. Semin. Oncol. 25(7):12-18, 1998.
20. Ludwig H.: Anaemia of hematologic malignancies: What are the options? Semin. Oncol. 29 (3 suppl 18):45-54, 2002.
21. Markham A., Bryson H.M.: Epoetin alpha: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applifications. Drugs 20(2):317-333, 1995.
22. Raza A, et al.: Myelodysplastic syndromes patients with Evi-1 expression respond well to a combination with arsenic trioxide and thalidomide. Leuk. Res. 27(Suppl 1):S110-111, 2003.
23. Vey N, et al.: Arsenic trioxide in patients with myelodysplastic syndromes : preliminary results of a phase fi study. Leuk. Res. 27(Suppl 1):S111-112, 2001.
24. Yamada T., Tsurumi H., Kasahara S., Kara T., Sawada M., and Moriwaki H.: Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A. J. Cane. Res. Clin. Oncol. 129(8):485-491, 2003.
25. Bram S., Swolin B., Rodjer S., Stockelberg D., Organd I., Back H.: Is monosomy 5 an uncommon aberration? Fluorescence in situ hybridization reveals translocations and deletions in myelodysplastic syndromes or acute myelocytic leukemia. Cancer Genet. Cytogenet. 142(2):107-114, 2003.
26. Horiike S., Kita- Sasai Y., Nakao M., Taniwaki M.: Configuration of TP 53 gene as an independent prognostic parameter of myelodysplastic syndrome. Leuk. Lymphoma 44(6):915-922, 2001.
27. Negrin R.S., Stein R., Doherty K., Cornuell J., Vardiman J., Krantz S. and Greenberg P.L.: Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87:4076-4081, 1996.
28. Mufti G.J., Stevens J.R., Oscier D.G., Hamblin T.J. and Machin D.: Myelodysplastic syndromes: a scoring system with prognostic significance. Br. J. Hematol. (59);425-433, 1985.
29. Geissler R.G., Schulte P. and Cancer A.: Treatment with growth factor in myelodysplastic syndromes. Pathologic Biologic (Paris) 45:656-667, 1997.
30. Terpos E. et al.: For the Greek MDS Study Group:Prolonged administration of erythropoietin increases erythroid response rate in the myelodysplastic syndromes: a phase II trial in 281 patients. Br. J. Hematology. 118(1):174-180, 2002.
31. Hellström-Lidberg E.: Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. British Journal of Haematology 89:67-71, 1995.
32. Italian Cooperative Study Group for rhuEpo in Myelodysplastic Syndromes; A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. British Journal of Haematology 103:1070-1074, 1998.
33. Mannervik B., Awasthi Y.C., Board P.G., Yayes J.D., Di Ilio C. et al.: Nomenclature for human glutathione transferases. Biochem. J. 15;282(p+1):305-306, 1992.
34. Board P.G.: Biochemical genesis of glutathione S-transferases in man. Am. J. Hum. Genet. 33(1):36-43, 1981.
35. Board P.G.: Gene deletion and partial deficiency of the glutathione transferases (ligandin) system in man. FEBS Lett. 30;135(1):12-14, 1981.
36. Cheh M., Shandler D.R., Taylor J.A., Lhore D.L., Lin E., Bloomfield C.D. et al.: Increased risk for myelodysplastic syndromes in individuals with glutathione transferases theta 1 (GSTT1) gene defect. Lancet 3;347 (8997):295-297, 1996.
37. Board P.G.: Gene deletion and partial deficiency of the glutathione transferases (ligandin) system in man. FEBS Lett. 30;135(1):12-14, 1981.
38. Tsabouri S.E., Georgiou I., Alamanos I. and Bourantas K.L.: Increased prevalence of GSTM1 null genotype in patients with myelodysplastic syndrome. Acta Hematologica 104:169-173, 2000.
39. Joncourt F., Oberli-Schrammli A.E., Stadler M., Buser K., Franscini L., Fey M.F. and Cerny T.: Patterns of drug resistance parameters in adult leukemia. Leuk. Lymphoma 17:101-109, 1995.
40. Bai F., Nakanishi Y., Kawasaki M., Takayama K., Yatsunami J., Pei X.H., Tsuruta N., Wakamatsu K. and Kara N.: Immunohistochemical expression of glutathione S-transferase Pi can predict chemotherapy response in patients with small cell lung carcinoma. Cancer 78:416-421, 1996.
41. Hamada S.J., Kamada M., Furumoto H., Hirao T. and Aono T.: Expression of glutathione S-transferase-Pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol. Oncol. 52:313-319, 1994.
42. Green J.A., Robertson L.J. and Clark A.H.: Gluathione S-transferase expression in benign and malignant ovarian tumors. Cr. J. Cancer 68:235-239, 1993.
43. Hirazono K., Shinozuka T., Kuroshima J., Itoh H. and Kawai K.: Immunohistolochemical expression of glutathione S-transferase-pi (GST-pi) and chemotherapy response in malignant ovarian tumors. J. Obstet. Gynecol. 21:305-312, 1995.
44. Rose E.H., Abels R.L., Nelson R.A., McCullough D.M. et Lessin L.: The use of rhuEpo in the treatment of anemia related to myelodysplasia (MDS). British Journal of Haematology 89:831-837, 1995.
45. Strenke L., Wallvik J., Celsing F., Hast R.: Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 7:1324-1327, 1993.
46. Bourantas K.L., Christou L., Tsiara St., Seferiadis K.: Myelodysplastic syndromes: Erythropoietin level and treatment with recombinant human erythropoietin. J. Exp. Clin. Cancer Res. 14(2):205-209, 1995.